Fig. 2From: Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort studyRisk of cardiovascular disease events associated with increasing durations of exposure to abacavir as compared to those never exposed. See Table 3 and S4 table for covariate adjustmentBack to article page